BELLEVILLE, ON,
Jan. 7, 2014 /CNW/ - Bioniche Life
Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage
biotechnology company, today announced the appointment of
Donald Olds as Chief Operating
Officer, effective immediately.
Dr. Michael
Berendt, CEO of Bioniche Life Sciences Inc., highlighted
that, "the engagement of Donald Olds
as Chief Operating Officer is the next step in our operational plan
to position Bioniche Life Sciences as a top-tier North American
biotechnology company with a focus on the development of oncology
therapeutics. Don brings a rare combination of scientific,
operational, and financial acumen that we are confident will help
us position our human therapeutic business for future success and
permit us to achieve our other operational objectives, including
the licensing and divestiture of our non-core business assets and
the implementation of operating cost reductions."
Prior to his new position with Bioniche Life
Sciences, Mr. Olds has held key executive positions in
biotechnology, investment banking, biotechnology and information
technology where he has led successful licensing, merger and
acquisition and debt and equity transactions for public and private
companies.
He currently serves as Chairman of the Board, of
the Neomed Institute (www.neomed.ca), is Director and Chair
of the Audit Committee of the Centre Quebecois (www.cqdm.org), is a
Director of Bellus Health (TSX: BLU), and is Treasurer of Oxfam
Quebec (www.oxfam.qc.ca). Mr. Olds has a M.Sc. (University of British Columbia) and a MBA - Finance
& Strategy (McGill University).
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and
innovative products for the global human health market. The
Company's primary goal is to develop and commercialize products
that advance human or animal health and increase shareholder
value.
For more information, please visit
www.Bioniche.com.
Except for historical information, this news
release may contain forward-looking statements that reflect the
Company's current expectation regarding future events. These
forward-looking statements involve risk and uncertainties, which
may cause, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties
related to the regulatory approval process, and other risks
detailed from time to time in the Company's ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.